MedTrace Logo

A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

NCT07160816 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2026-04-06

No results posted yet for this study

Summary

The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin icodec

Participants with T1D will be treated with commercially available insulin icodec.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2027-01-20
Completion
2027-01-20

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07160816 on ClinicalTrials.gov